On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b study to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Additionally, the second Canadian site, in Calgary, Alberta, had also been initiated.

A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, was planned.